Sambrinvest

Sambrinvest S.A. is a private equity and venture capital firm located in Gosselies, Belgium, established in 1985. The firm specializes in direct and fund of funds investments, focusing on small and medium-sized enterprises primarily in the Charleroi Sud-Hainaut and Thuin districts. Sambrinvest targets various sectors including agri-food, audiovisual, gaming, automotive, biotechnology, pharmaceuticals, construction, digital technology, environmental solutions, alternative energy, manufacturing, and real estate, while excluding retail, hospitality, and banking. The firm typically invests through minority stakes, subordinated loans, and other financial instruments, with investment amounts generally not exceeding €1.25 million in companies with revenues below €50 million. Sambrinvest is recognized as an active venture capital player in its region and remains open to opportunities in additional sectors.

Géraldine Crosset

Investment Manager - Life Sciences

Xavier Daive

COO and Head of Unit

Grégoire Dupuis

CEO

Gilles Groignet

Investment Manager

Elisabeth de Halleux

Investment Manager - Life Sciences

Soon Lambert

Investment Manager

Helena Pozios

Chief Investment Officer

Yasmine Preyat

Investment Manager

Anne Prignon

Managing Director

Zoubir Sefsaf

CFO

Past deals in Belgium

Aerospacelab

Series B in 2022
Aerospacelab SA, founded in 2017 and headquartered in Mont-Saint-Guibert, Belgium, specializes in the development and manufacturing of small satellites equipped with advanced sensors. The company focuses on addressing complex challenges through innovative solutions, including the use of artificial intelligence and machine learning to automate various tasks. Aerospacelab's technology enables the collection of high-resolution optical data and provides a platform that facilitates the analysis of large datasets. This capability allows customers to effectively survey and monitor diverse applications, optimizing the transformation of the information gathered.

PDC*line Pharma

Series B in 2021
PDC*line Pharma is a French-Belgium clinical-stage biotech company that develops a new class of active immunotherapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line) loaded with cancer antigens. PDC*line Pharma originated from a flagship R&D program of the French Blood Bank (EFS, Etablissement Français du Sang) where PDC*line, a proprietary Plasmacytoid Dendritic Cell line (PDC) was developed from a patient with a PDC leukemia. Laurent LEVY President France & COO, and Joel PLUMAS, CSO founded the company in April 2014 in Grenoble and took the project to the clinical development stage with non-dilutive funding. Eric Halioua joined the team in February 2016, and became President and CEO in July 2016.

ExeVir Bio

Series A in 2020
ExeVir Bio BV, founded in 2020 and based in Zwijnaarde, Belgium, specializes in developing single-domain antibody-based therapies aimed at combating viral infections. The company leverages a llama-derived antibody technology platform to create robust antiviral treatments that offer broad protection against coronaviruses. Notably, it is developing VHH72-FC, an antibody that targets a highly conserved region on the spikes of SARS-CoV-2, crucial for the virus's entry into human cells. ExeVir Bio's rapid response platform for antivirals allows for an agile approach to emerging health threats, enabling the swift generation of drug candidates. The therapeutics produced through this innovative technology are designed to be stable, cost-effective, and accessible on a global scale.

PDC*line Pharma

Series B in 2020
PDC*line Pharma is a French-Belgium clinical-stage biotech company that develops a new class of active immunotherapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line) loaded with cancer antigens. PDC*line Pharma originated from a flagship R&D program of the French Blood Bank (EFS, Etablissement Français du Sang) where PDC*line, a proprietary Plasmacytoid Dendritic Cell line (PDC) was developed from a patient with a PDC leukemia. Laurent LEVY President France & COO, and Joel PLUMAS, CSO founded the company in April 2014 in Grenoble and took the project to the clinical development stage with non-dilutive funding. Eric Halioua joined the team in February 2016, and became President and CEO in July 2016.

Utopix Pictures

Seed Round in 2019
Utopix Pictures SA is a Belgium-based company founded in 2015 that operates a platform designed to connect users with professionals in the photography, film, and imaging sectors. The company aims to simplify the process of finding the right photographer or videographer to meet specific project needs. By leveraging a network of skilled professionals, Utopix Pictures assists clients in transforming their ideas into compelling visual content efficiently and effectively.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.